A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
Conditions: Chronic Kidney Diseases; Pruritus Interventions: Drug: CR845 0.25 mg Oral Tablet; Drug: CR845 0.5 mg Oral Tablet; Drug: CR845 1 mg Oral Tablet; Drug: Placebo Oral Tablet Sponsor: Cara Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials